The Process Development Blog

APC & VLE Therapeutics have been named BioPharma Company of the Year, recognising The Medicine Accelerator’s Irish-led approach to process science, digital CMC, and GMP-ready medicine development.

HPRA is baseline. An integrated PD→GMP model with a single digital backbone improves clinical readiness, shortening time to batch start and boosting right-first-time.

APC & VLE Therapeutics is looking forward to seeing you at CPHI, in Tokyo which brings together upstream, downstream, bioproduction, analytical, and formulation professionals to advance the manufacture, quality, and control of biological and genetic therapies.

APC & VLE Therapeutics is looking forward to seeing you at PD2M, in Cambridge, MA which brings together upstream, downstream, bioproduction, analytical, and formulation professionals to advance the manufacture, quality, and control of biological and genetic therapies.

APC & VLE Therapeutics is looking forward to seeing you at Bioprocess International Europe, in Vienna which brings together upstream, downstream, bioproduction, analytical, and formulation professionals to advance the manufacture, quality, and control of biological and genetic therapies.

In this presentation, Ciara McDonnell, from APC’s process development team, delves into multistep synthetic projects, using two case studies to illustrate APC's end-to-end approach process development and characterisation.

FDA’s 2025 approvals show biologics growing more complex. Learn why next-gen modalities demand stronger analytics, process design, and integrated CMC strategies.

APC & VLE Therapeutics is looking forward to seeing you at Bioprocessing Summit Europe which brings together upstream, downstream, bioproduction, analytical, and formulation professionals to advance the manufacture, quality, and control of biological and genetic therapies.

The Medicine Accelerator is thrilled to exhibit at Advanced Therapies, London 2026! Stop by and say hello!